Certara (NASDAQ:CERT) Reports Quarterly Earnings Results, Falls Short of Forecasts

Certara (NASDAQ:CERT) announced its quarterly earnings results on Wednesday, reporting earnings of $0.12 per share (EPS) for the quarter. This figure fell short of analysts' expectations, which predicted a consensus EPS of $0.13, resulting in a miss of $0.01. The company also reported a negative net margin of 8.34% and a positive return on equity of 3.43%. Furthermore, Certara has adjusted its guidance for FY 2025 to project an EPS range of $0.420 to $0.460.

Certara Stock Performance

On Wednesday, Certara’s stock experienced a slight decline, falling 0.4%, or $0.05, to finish at $12.33. The trading volume for the day was 1,222,313 shares, which is lower than the average daily volume of 1,274,044 shares. Throughout the year, Certara's stock has reached a 52-week low of $9.41 and a high of $19.87. The stock's 50-day simple moving average stands at $12.36, while the 200-day simple moving average is $11.63. The company currently holds a market capitalization of $1.98 billion, with a P/E ratio of -61.65 and a PEG ratio of 9.29. Additionally, Certara has a quick ratio and a current ratio both at 2.86, indicating good liquidity, and a debt-to-equity ratio of 0.28, suggesting manageable debt levels.

Analyst Ratings and Future Outlook

Several analysts have recently analyzed Certara’s stock. Robert W. Baird lowered its price target from $18.00 to $13.00 and assigned a "neutral" rating. Barclays also cut its price objective from $14.00 to $12.00 while maintaining an "equal weight" rating. Currently, out of eight investment analysts, six have given the stock a hold rating, and two have issued a buy rating. According to data from MarketBeat.com, Certara has an average consensus rating of "Hold" with a price target averaging $15.92.

About Certara

Certara, Inc., along with its subsidiaries, specializes in providing software products and technology-enabled services to assist clients in biosimulation, particularly in drug discovery, preclinical and clinical research, regulatory submissions, and market access, both in the United States and internationally. Their solutions facilitate model-informed drug development and biosimulation, helping to predict both pharmacokinetics and pharmacodynamics.

Earnings, Stocks, Analysis